Drug Resistance to Integrase Strand-Transfer Inhibitors among HIV-1-Infected Adults in Guangdong, China

Drug Resistance to Integrase Strand-Transfer Inhibitors among HIV-1-Infected Adults in Guangdong, China

Background: Integrase strand-transfer inhibitor (INSTI)-containing regimens have gradually been administered in Guangdong Province, China beginning in 2016, and INSTI-related drug resistance (DR) may occur and should be monitored among HIV-1-infected patients. Objective: To investigate the prevalenc...

Full description

Bibliographic Details
Main Authors:	Yun Lan, Linghua Li, Ruolei Xin, Xuemei Ling, Xizi Deng, Junbin Li, Liya Li, Weiping Cai, Feng Li, Fengyu Hu
Format:	Article
Language:	English
Published:	MDPI AG 2022-11-01
Series:	Pathogens
Subjects:	HIV-1 drug resistance mutations integrase strand transfer inhibitors drug resistance
Online Access:	https://www.mdpi.com/2076-0817/11/11/1321

Similar Items

Prevalence and analysis of acquired and transmitted integrase strand transfer inhibitor-associated HIV-1 drug resistance in Chongqing, China
by: Huizheng Zhang, et al.
Published: (2023-12-01)

Low prevalence of archived integrase strand transfer inhibitors resistance associated mutations in Botswana before the roll out of dolutegravir based first line antiretroviral therapy
by: Dorcas Maruapula, et al.
Published: (2024-10-01)

Factors associated with HIV-1 resistance to integrase strand transfer inhibitors in Spain: Implications for dolutegravir-containing regimens
by: Horacio Gil, et al.
Published: (2022-12-01)

No transmitted drug resistance to HIV integrase strand-transfer inhibitors after their scale-up in Estonia in 2017
by: Arina Šablinskaja, et al.
Published: (2023-06-01)

Prevalence of resistance mutations associated with integrase inhibitors in therapy-naive HIV-positive patients in Baoding, Hebei province, China
by: Weiguang Fan, et al.
Published: (2022-09-01)

Frequency of Major Transmitted Integrase Resistance in Poland Remains Low Despite Change in Subtype Variability
by: Kaja Mielczak, et al.
Published: (2024-10-01)

Drug Resistance to HIV-1 Integrase Inhibitors Among Treatment-Naive Patients in Beijing, China
by: Yu F, et al.
Published: (2022-03-01)

First Reported Case of Integrase Strand Transfer Inhibitor Resistance in Suriname: Unusual Drug Resistance Mutations Following Exposure to Dolutegravir
by: Rachel C. Sno, et al.
Published: (2025-02-01)

HIV-1 Integrase Strand Transfer Inhibitors and Neurodevelopment
by: Emma G. Foster, et al.
Published: (2022-12-01)

Different Pathways Conferring Integrase Strand-Transfer Inhibitors Resistance
by: Clémence Richetta, et al.
Published: (2022-11-01)

Inhibition of matrix metalloproteinases by HIV-1 integrase strand transfer inhibitors
by: Emma G. Foster, et al.
Published: (2023-02-01)

Drug resistance mutations to integrase inhibitors, proteinase, and reverse transcriptase inhibitors in newly diagnosed HIV-1 infections in Hebei province, China, 2018–2022
by: Xinli Lu, et al.
Published: (2025-02-01)

Emergent dolutegravir resistance in integrase-naïve, treatment experienced patients from Zimbabwe
by: Linda A. Mandikiyana Chirimuta, et al.
Published: (2022-10-01)

Structural Implications of Genotypic Variations in HIV-1 Integrase From Diverse Subtypes
by: Leonard Rogers, et al.
Published: (2018-08-01)

Molecular evolution of HIV-1 integrase during the 20 years prior to the first approval of integrase inhibitors
by: Karolin Meixenberger, et al.
Published: (2017-11-01)

Comparative Analyses of Antiviral Potencies of Second-Generation Integrase Strand Transfer Inhibitors (INSTIs) and the Developmental Compound 4d Against a Panel of Integrase Quadruple Mutants
by: Steven J. Smith, et al.
Published: (2025-01-01)

First report of computational protein–ligand docking to evaluate susceptibility to HIV integrase inhibitors in HIV-infected Iranian patients
by: Farzane Ghasabi, et al.
Published: (2022-07-01)

Drug-selective pressure effect on HIV integrase mutations in antiretroviral naïve and experienced patients
by: Parya Basimi, et al.
Published: (2023-04-01)

From protease inhibitors to integrase strand transfer inhibitors: the evolution of HIV drug resistance management
by: HU Zhiliang, YANG Yongfeng
Published: (2025-01-01)

Efficacy of Integrase Strand Transfer Inhibitors and the Capsid Inhibitor Lenacapavir against HIV-2, and Exploring the Effect of Raltegravir on the Activity of SARS-CoV-2
by: Irene Wanjiru Kiarie, et al.
Published: (2024-10-01)

HIV-1 Subtype C Drug Resistance Mutations in Heavily Treated Patients Failing Integrase Strand Transfer Inhibitor-Based Regimens in Botswana
by: Kaelo K. Seatla, et al.
Published: (2021-03-01)

Clinical Outcomes of Integrase Strand Transfer Inhibitors Containing Antiretroviral Therapy in HIV-2: A Narrative Review
by: Wendy J. Boschloo, et al.
Published: (2024-05-01)

Treatment Emergent Dolutegravir Resistance Mutations in Individuals Naïve to HIV-1 Integrase Inhibitors: A Rapid Scoping Review
by: Kaiming Tao, et al.
Published: (2023-09-01)

A clinical review of HIV integrase strand transfer inhibitors (INSTIs) for the prevention and treatment of HIV-1 infection
by: Alexa Vyain Zhao, et al.
Published: (2022-10-01)

Emergence of the G118R Pan-Integrase Resistance Mutation as a Result of Low Compliance to a Dolutegravir-Based cART
by: Helene Mens, et al.
Published: (2022-06-01)

Risk of Cardiovascular Events in People with HIV (PWH) Treated with Integrase Strand-Transfer Inhibitors: The Debate Is Not Over; Results of the SCOLTA Study
by: Nicolò Corti, et al.
Published: (2024-04-01)

Factors associated with incomplete adherence to integrase strand transfer inhibitor-containing single-tablet regimen among Japanese people living with HIV
by: Yusuke Kunimoto, et al.
Published: (2024-06-01)

Real-world prevalence of integrase inhibitor resistance and virological failure since adoption as guideline-preferred therapy
by: Jenna Januszka, et al.
Published: (2024-05-01)

Pre-Treatment Integrase Inhibitor Resistance and Natural Polymorphisms among HIV-1 Subtype C Infected Patients in Ethiopia
by: Dawit Assefa Arimide, et al.
Published: (2022-03-01)

Exploring Zinc C295 as a Dual HIV-1 Integrase Inhibitor: From Strand Transfer to 3′-Processing Suppression
by: Sharif Karim Sayyed, et al.
Published: (2024-12-01)

Comprehensive Analysis of HIV-1 Integrase Resistance-Related Mutations in African Countries
by: Francesco Branda, et al.
Published: (2024-01-01)

Effectiveness and safety of integrase strand transfer inhibitors in Spain: a prospective real-world study
by: José Ramón Santos, et al.
Published: (2023-06-01)

The structural and mechanistic bases for the viral resistance to allosteric HIV-1 integrase inhibitor pirmitegravir
by: Tung Dinh, et al.
Published: (2024-11-01)

Integrase Strand Transfer Inhibitors Are Effective Anti-HIV Drugs
by: Steven J. Smith, et al.
Published: (2021-01-01)

Outcomes of switching from protease inhibitor-based antiretroviral therapy to bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) in virologically suppressed adults with nucleos(t)ide analogue resistance– a phase IV randomised, open-label study (PIBIK study)
by: Collins Iwuji, et al.
Published: (2025-02-01)

Epidemic trend, genetic characteristics, and transmission networks of HIV-1 among treatment-naive men who have sex with men in Hebei province, China
by: Xinli Lu, et al.
Published: (2024-08-01)

Integrase-RNA interactions underscore the critical role of integrase in HIV-1 virion morphogenesis
by: Jennifer L Elliott, et al.
Published: (2020-09-01)

A Partially Multiplexed HIV Drug Resistance (HIVDR) Assay for Monitoring HIVDR Mutations of the Protease, Reverse-Transcriptase (PRRT), and Integrase (INT)
by: Joshua DeVos, et al.
Published: (2022-06-01)

Inhibitors of the integrase–transportin-SR2 interaction block HIV nuclear import
by: Jonas Demeulemeester, et al.
Published: (2018-01-01)

Dolutegravir Plus Lamivudine Two-Drug Regimen: Safety, Efficacy and Diagnostic Considerations for Its Use in Real-Life Clinical Practice—A Refined Approach in the COVID-19 Era
by: Valeria Cento, et al.
Published: (2021-04-01)